微血管灌注MRI改善胶质瘤治疗监测并早期检出复发:一项2000次随访检查的大规模试验
该回顾性研究纳入351例胶质瘤患者的2003次随访MRI检查,其中422次进行定量分析,评估基于自旋回波DSC灌注MRI的微血管灌注(µPerf)技术对比常规MRI(cMRI)早期检出胶质瘤复发的价值。µPerf的诊断准确率达97.4%,微血管类型指标AUROC为0.987、微血管CBV的AUROC为0.982,均显著优于cMRI(准确率85.1%、CBV的AUROC 0.941);µPerf在13.5%的病例中比cMRI更早检出复发,提前41至353天(平均137天)。作者结论认为µPerf可改善胶质瘤复发的早期检出,但将其整合入临床实践尚需多中心研究和长期结局分析进一步验证。
要点
- µPerf诊断准确率97.4%,微血管类型指标AUROC 0.987、微血管CBV AUROC 0.982,均优于cMRI。
- µPerf在13.5%病例中比cMRI提前41–353天(平均137天)检出胶质瘤复发。
- 高级别恶性胶质瘤的早期复发以微血管改变为主,区别于较晚期的复发。
核心结论
- µPerf可改善胶质瘤复发的早期检出,对微血管改变的敏感性高于cMRI;µPerf具有促进更及时和个体化治疗策略的显著潜力,从而可能改善患者结局。
研究设计与样本
- 回顾性评估351例胶质瘤患者的2003次随访MRI检查,其中422次检查接受详细定量分析;标准cMRI方案扩展应用µPerf方法,数据采集额外增加2分钟;使用自制Matlab软件生成微血管CBV和微血管类型指标的影像生物标志物图;cMRI数据由至少2名委员会认证的放射科医生共识判读作为对比;统计分析包括诊断性能指标和AUROC计算。
关键影像表现/征象
- µPerf在13.5%的病例中比cMRI更早检出胶质瘤复发,时间间隔为41至353天(平均137天)。
- 在该提前检出的时间窗内,肿瘤体积增加38%至高达155倍(平均9.1倍)。
- 高级别恶性胶质瘤的早期复发与较晚期复发相比,主要以微血管改变为特征。
诊断标准与关键数值
- µPerf技术诊断准确率为97.4%。
- µPerf微血管类型指标的AUROC为0.987(95% CI,0.976-0.999)。
- µPerf微血管CBV的AUROC为0.982(95% CI,0.965-0.998)。
- cMRI诊断准确率为85.1%,CBV的AUROC为0.941(95% CI,0.918-0.965)。
临床应用与阅片要点
- µPerf可与标准临床随访方案配合使用,数据采集仅需额外增加2分钟。
- 作者指出µPerf整合入临床实践尚需通过多中心研究和长期结局分析进一步验证。
局限性
- 原文指出µPerf整合入临床实践需通过多中心研究和长期结局分析进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Detecting glioma recurrence is fundamental for clinical patient outcomes; however, conventional MRI (cMRI) techniques may be limited, leading to diagnostic uncertainty relevant for therapeutic intervention. This study aimed to evaluate whether a microvascular perfusion (µPerf) imaging technique based on spin-echo DSC perfusion MRI could support the early detection of glioma recurrence compared with cMRI by characterizing subtle vascular changes preceding macroscopic tumor growth.
MATERIALS AND METHODS: A total of 351 patients with gliomas who underwent 2003 follow-up MRI examinations were retrospectively evaluated, with 422 of these examinations subjected to detailed quantitative analysis. The standard cMRI protocol was extended by applying the µPerf approach, with an additional 2 minutes for data acquisition. Custom-made Matlab software was used to generate imaging biomarker maps for microvascular CBV and microvascular type indicator. The clinical utility of µPerf was assessed by comparing its findings with radiologic interpretations of cMRI data, which were reviewed in consensus by at least 2 board-certified radiologists. Statistical analyses included the calculation of diagnostic performance metrics and the area under the receiver operating characteristic curve (AUROC) to evaluate glioma recurrence detection.
RESULTS: The µPerf technique exhibited superior diagnostic performance, achieving an accuracy of 97.4% and AUROC values of 0.987 (95% CI, 0.976-0.999) for microvascular type indicator and 0.982 (95% CI, 0.965-0.998) for microvascular CBV, significantly surpassing cMRI (accuracy: 85.1%; AUROC: 0.941; 95% CI, 0.918-0.965 for CBV). µPerf identified glioma recurrence earlier than cMRI in 13.5% of cases, with the time interval ranging from 41 to 353 days (mean, 137 days). During this time, tumor volume increased by 38% to as much as 155-fold (mean, 9.1-fold). Notably, early recurrences of high-grade malignant gliomas were predominantly characterized by microvascular changes compared with later-stage recurrences.
CONCLUSIONS: µPerf improves early detection of glioma recurrence and shows a higher sensitivity of microvascular changes compared with cMRI. µPerf has significant potential to promote more timely and personalized treatment strategies, which, in turn, could improve patient outcomes. Notably, µPerf works with standard clinical follow-up protocols, but its integration into clinical practice requires further validation through multicenter studies and long-term outcome analyses.
引用
- Stadlbauer A, Nikolic K, Marhold F, et al. Microvascular Perfusion MRI Improves Therapy Monitoring and Detects Early Recurrences of Gliomas: A Large-Scale Trial of 2000 Follow-Up Examinations. AJNR Am J Neuroradiol. 2025. PMID: 41344846. doi:10.3174/ajnr.A8922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。